Study Supports Delay of CDK4/6 Inhibitors Until Second-Line Treatment in Advanced HR+/HER2- Breast Cancer

被引：0
|
作者：
Rugo, Hope S. [1 ]
机构：
[1] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94158 USA
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2023年 / 21卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：352 / 353
页数：2
相关论文
共 50 条
  • [1] CDK4/6 inhibitors combined with fulvestrant for HR+/HER2- advanced breast cancer
    Zhang, Jie
    Hao, Chunfang
    TRANSLATIONAL BREAST CANCER RESEARCH, 2022, 3
  • [2] Cost-effectiveness of CDK4/6 inhibitors for second-line HR+/HER2− advanced or metastatic breast cancer in China
    Caifeng Jia
    Sen Zhang
    Jie Wang
    Bing Feng
    Fenghao Shi
    Meiqi Wang
    Sainan Li
    Hao Xu
    Mingxia Wang
    Scientific Reports, 15 (1)
  • [3] Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2-advanced breast cancer
    Corona, Silvia Paola
    Generali, Daniele
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2018, 12 : 321 - 330
  • [4] Circumvent hesitancy between CDK4/6 and mTOR inhibitors in second-line treatment of HR+, erb2-metastatic breast cancer
    El Rassy, Elie
    Abdayem, Pamela
    Kattan, Joseph
    FUTURE ONCOLOGY, 2017, 13 (17) : 1451 - 1453
  • [5] Optimizing CDK4/6 inhibitors in advanced HR+/HER2-breast cancer: A personalized approach
    Fontanella, Caterina
    Giorgi, Carlo Alberto
    Russo, Stefania
    Angelini, Silvia
    Nicolardi, Linda
    Giarratano, Tommaso
    Frezzini, Simona
    Pestrin, Marta
    Palleschi, Dario
    Bolzonello, Silvia
    Parolin, Veronica
    Haspinger, Eva R.
    De Rossi, Costanza
    Greco, Filippo
    Gerratana, Lorenzo
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2022, 180
  • [6] Patients with HR+/HER2- metastatic breast cancer treated with CDK4/6 inhibitors: a real-world study in Italy
    Perrone, Valentina
    Dovizio, Melania
    Leogrande, Melania
    Tamma, Antonella
    Giovannitti, Massimo
    Buzzoni, Carlotta
    Esposti, Luca Degli
    BREAST CANCER MANAGEMENT, 2023, 12 (02)
  • [7] Breast Cancer CDK4/6 Inhibitors in Patients with metastatic HR+/HER2-Breast Cancer
    Schmale, Ine
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 (1-2)
  • [8] Approaching Use of CDK4/6 Inhibitors in Metastatic HR+, HER2-Breast Cancer
    Weiss, Jennifer
    Afghahi, Anosheh
    Shagisultanova, Elena
    Diamond, Jennifer R.
    ONCOLOGY-NEW YORK, 2018, 32 (10): : 513 - 515
  • [9] Therapy of HR+/HER2-advanced Breast Cancer CDK4/6 Inhibitors: Studies, Everyday Healthcare and Guidelines
    Ruedesheim, Sabine M.
    BREAST CARE, 2021, 16 (03)
  • [10] CDK4/6 inhibitors in advanced HR+/HER2-breast cancer - a multicenter real world data analysis
    Mueller, C.
    Kiver, V
    Solomayer, E-F
    Wagenpfeil, G.
    Neeb, C.
    Blohmer, J. U.
    Abramian, A., V
    Maass, N.
    Schuetz, F.
    Kolberg-Liedtke, C.
    Ralser, D. J.
    Rambow, A-C
    BREAST CARE, 2023, 18 (01) : 31 - 41
12345